Loss of exclusivityJune 2035latest FDA-listed patent expiry
CompanyCERVEAU TECHNOLOGIES INC A LANTHEUS CO
Drug detail
Brand name
TAUKLARIFY
Active ingredient
FLORQUINITAU F-18
Strength
1-40mCi/ML
Dosage form
SOLUTION
Route
INTRAVENOUS
Modality
Small molecule
FDA approval
August 2026
Marketing status
RX
Listed patents
Patent
Expires
Type
9808542
June 2035
substance, product
10022461
June 2035
use U-4597
Regulatory exclusivity
Code
Expires
NCE
August 2031
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.